Show simple item record

dc.contributor.authorKonishi, Eiji
dc.contributor.authorKurane, Ichiro
dc.contributor.authorMason, Peter W.
dc.contributor.authorShope, Robert E.
dc.contributor.authorKanesa-Thasan, Niranjan
dc.contributor.authorSmucny, John J.
dc.contributor.authorHoke, Charles H. Jr
dc.contributor.authorEnnis, Francis A.
dc.date2022-08-11T08:09:10.000
dc.date.accessioned2022-08-23T16:19:40Z
dc.date.available2022-08-23T16:19:40Z
dc.date.issued1998-05-01
dc.date.submitted2017-11-13
dc.identifier.citationVaccine. 1998 May;16(8):842-9. <a href="https://doi.org/10.1016/S0264-410X(97)00265-X">Link to article on publisher's website</a>
dc.identifier.issn0264-410X (Linking)
dc.identifier.doi10.1016/S0264-410X(97)00265-X
dc.identifier.pmid9627942
dc.identifier.urihttp://hdl.handle.net/20.500.14038/35103
dc.description.abstractPoxvirus-based recombinant Japanese encephalitis (JE) vaccine candidates, NYVAC-JEV and ALVAC-JEV, were examined for their ability to induce JE virus-specific cytotoxic T lymphocytes (CTLs) in a phase I clinical trial. These vaccine candidates encoded the JE virus premembrane (prM), envelope (E) and non-structural 1 (NS1) proteins. The volunteers received subcutaneous inoculations with each of these candidates on days 0 and 28, and blood was drawn 2 days before vaccination and on day 58. Anti-E and anti-NS1 antibodies were elicited in most vaccinees inoculated with NYVAC-JEV and in some vaccinees inoculated with ALVAC-JEV. Peripheral blood mononuclear cells (PBMCs) obtained from approximately one half of vaccines showed positive proliferation in response to stimulation with live JE virus. Cytotoxic assays demonstrated the presence of JE virus-specific CTLs in in vitro-stimulated PBMCs obtained from two NYVAC-JEV and two ALVAC-JEV vaccinees. Cell depletion tests using PBMCs from one NYVAC-JEV recipient indicated that the phenotype of CTLs was CD8+CD4-.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=9627942&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttps://doi.org/10.1016/S0264-410X(97)00265-X
dc.subjectImmunity
dc.subjectImmunology and Infectious Disease
dc.subjectImmunology of Infectious Disease
dc.subjectInfectious Disease
dc.subjectVirology
dc.titleInduction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates
dc.typeJournal Article
dc.source.journaltitleVaccine
dc.source.volume16
dc.source.issue8
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/infdis_pp/312
dc.identifier.contextkey11035647
html.description.abstract<p>Poxvirus-based recombinant Japanese encephalitis (JE) vaccine candidates, NYVAC-JEV and ALVAC-JEV, were examined for their ability to induce JE virus-specific cytotoxic T lymphocytes (CTLs) in a phase I clinical trial. These vaccine candidates encoded the JE virus premembrane (prM), envelope (E) and non-structural 1 (NS1) proteins. The volunteers received subcutaneous inoculations with each of these candidates on days 0 and 28, and blood was drawn 2 days before vaccination and on day 58. Anti-E and anti-NS1 antibodies were elicited in most vaccinees inoculated with NYVAC-JEV and in some vaccinees inoculated with ALVAC-JEV. Peripheral blood mononuclear cells (PBMCs) obtained from approximately one half of vaccines showed positive proliferation in response to stimulation with live JE virus. Cytotoxic assays demonstrated the presence of JE virus-specific CTLs in in vitro-stimulated PBMCs obtained from two NYVAC-JEV and two ALVAC-JEV vaccinees. Cell depletion tests using PBMCs from one NYVAC-JEV recipient indicated that the phenotype of CTLs was CD8+CD4-.</p>
dc.identifier.submissionpathinfdis_pp/312
dc.contributor.departmentDepartment of Medicine, Division of Infectious Diseases and Immunology
dc.contributor.departmentCenter for Infectious Disease and Vaccine Research
dc.source.pages842-9


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record